XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America
ConclusionsXANTUS-EL confirmed low stroke and major bleeding rates in patients with NVAF from EEMEA and Latin America. The population was younger but with more heart failure and hypertension than XANTUS; stroke/SE rate was similar but major bleeding lower.
Source: The Egyptian Heart Journal - Category: Cardiology Source Type: research
More News: African Health | Atrial Fibrillation | Bleeding | Canada Health | Cardiology | Diabetes | Diabetes Mellitus | Egypt Health | Endocrinology | Heart | Heart Attack | Heart Failure | Hypertension | Ischemic Stroke | Israel Health | Middle East Health | Stroke | Study